Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.